Pharmaceutical-manufactured peptides, delivered in a certified injector pen. No reconstitution, no syringe, no arithmetic at the patient end — the patient selects a dose and the device meters it.
Three things have to be right at once: the device, the compound, and the facility that put one inside the other. Each is documented on its own page.
Two device tiers on one dosing platform. 0.01 mL per click, audible and tactile, on a 3 mL ISO 11608-2 cartridge. Sixty independent measurements, zero failures.
Metabolic and GLP-1, growth hormone secretagogues, repair and regenerative, melanocortins, neuroactive and longevity, immune and established actives.
Three tiers supply this market. Only one holds a national drug manufacturing license and cannot ship without formal QA release. That is the tier supplying Med Plug RX.
Insulin took two decades. GLP-1 took five — in front of the same patients now asking about peptides. They have already held a pen. Reconstitution survives here for one reason: the supply chain behind it was never pharmaceutical. That has changed.
Format transitions reward the earliest mover, not the best one. For a defined period you are not competing on price — you are offering something competitors cannot source.
Compete on experience while the format is scarce. Sterile cartridge filling, closure integrity validation and dose accuracy testing are not capabilities a compounding operation adds quickly.
Reorder behavior attaches to the delivery, not the compound. A patient who has dialed a dose does not go back to drawing one.
A pen is an object patients describe. A vial is not.
First mover is remembered as the name that introduced it. The constraint is upstream, and it is already solved.
Attrition concentrates at the first self-administration and the first reorder. Both are preparation events. Remove the preparation and you remove the moment the patient decides this is too much.
No measurement. No arithmetic. No judgment about whether the solution looks properly mixed.
The physicians on our register are building longevity, aesthetic and metabolic practice around characterized compounds. What we owe them is a supply that is documented, consistent and never substituted.
The patients now asking about peptides are the same patients who dialed a GLP-1 dose last year. The format they expect is the one they already know; anything else reads as a step backward.
A pen is an object patients describe to friends. A vial is not.
Accounts are verified against state licensure before a single pen moves. We do not sell to consumers, we do not list on marketplaces, and we do not discount to win an order.
For programs built around metabolic and cellular health, directed entirely by the physician.
For the practices where the result is visible, photographed and referred.
For specialists who demand the same lot-level record they demand everywhere else.
Samples of both device tiers are available to verified physician accounts, filled or unfilled. The full certification package and the 56-page laboratory report are released on NDA.
